US-based Regeneron Pharmaceuticals said on Thursday that it has begun human trials of its antibody 'cocktail' as a treatment for COVID-19. The antibody, called REGN-COV2, contains an antibody made by Regeneron and a second isolated from humans who recovered from COVID-19. The firm also plans to study REGN-COV2 for preventing the infection in people at high risk of exposure.